Literature DB >> 25954476

Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.

Treta Purohit1, Mitchell S Cappell1.   

Abstract

Primary biliary cirrhosis (PBC) is an autoimmune, slowly progressive, cholestatic, liver disease characterized by a triad of chronic cholestasis, circulating anti-mitochondrial antibodies (AMA), and characteristic liver biopsy findings of nonsuppurative destructive cholangitis and interlobular bile duct destruction. About 10% of PBC patients, however, lack AMA. A variant, called PBC-autoimmune hepatitis (AIH) overlap, is characterized by the above findings of PBC together with findings of elevated serum alanine aminotransferase, elevated serum immunoglobulin G, and circulating anti-smooth muscle antibodies, with liver biopsy demonstrating periportal or periseptal, lymphocytic, piecemeal necrosis. PBC is hypothesized to be related to environmental exposure in genetically vulnerable individuals. It typically occurs in middle-aged females. Prominent clinical features include fatigue, pruritis, jaundice, xanthomas, osteoporosis, and dyslipidemia. The Mayo Risk score is the most widely used and best prognostic system. Ursodeoxycholic acid is the primary therapy. It works partly by reducing the concentration and injury from relatively toxic bile acids. PBC-AIH overlap syndrome is treated with ursodeoxycholic acid and corticosteroids, especially budesonide. Obeticholic acid and fibrate are promising new, but incompletely tested, therapies. Liver transplantation is the definitive therapy for advanced disease, with about 70% 10-year survival after transplantation. Management of pruritis includes local skin care, dermatologist referral, avoiding potential pruritogens, cholestyramine, and possibly opioid antagonists, sertraline, or rifaximin. Management of osteoporosis includes life-style modifications, administration of calcium and vitamin D, and alendronate. Statins are relatively safe to treat the osteopenia associated with PBC. Associated Sjogren's syndrome is treated by artificial tears, cyclosporine ophthalmic emulsion to stimulate tear production; and saliva substitutes, cholinergic agents, and scrupulous oral and dental care. Complications of cirrhosis from advanced PBC include esophageal varices, ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and hepatoma formation.

Entities:  

Keywords:  Cholestatic liver disease; Cirrhosis; Liver transplantation; Primary biliary cirrhosis; Ursodeoxycholic acid

Year:  2015        PMID: 25954476      PMCID: PMC4419097          DOI: 10.4254/wjh.v7.i7.926

Source DB:  PubMed          Journal:  World J Hepatol


  218 in total

1.  Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.

Authors:  Masanobu Tsuda; Yuki Moritoki; Zhe-Xiong Lian; Weici Zhang; Katsunori Yoshida; Kanji Wakabayashi; Guo-Xiang Yang; Toshio Nakatani; John Vierling; Keith Lindor; M Eric Gershwin; Christopher L Bowlus
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

2.  Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis.

Authors:  E A Jones; L R Dekker
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

Review 3.  Pathogenesis and management of pruritus in cholestatic liver disease.

Authors:  Mohamad H Imam; Andrea A Gossard; Emmanouil Sinakos; Keith D Lindor
Journal:  J Gastroenterol Hepatol       Date:  2012-07       Impact factor: 4.029

4.  Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction.

Authors:  C Rose; R F Butterworth; J Zayed; L Normandin; K Todd; A Michalak; L Spahr; P M Huet; G Pomier-Layrargues
Journal:  Gastroenterology       Date:  1999-09       Impact factor: 22.682

Review 5.  Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment.

Authors:  Albert Parés; Núria Guañabens
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

Review 6.  Antimitochondrial antibody-negative primary biliary cirrhosis.

Authors:  Gideon M Hirschfield; E J Heathcote
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

7.  Fenofibrate in primary biliary cirrhosis: a pilot study.

Authors:  E N Liberopoulos; M Florentin; M S Elisaf; D P Mikhailidis; E Tsianos
Journal:  Open Cardiovasc Med J       Date:  2010-04-28

8.  The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group.

Authors: 
Journal:  J Hepatol       Date:  1993-02       Impact factor: 25.083

9.  Optimal timing of liver transplantation for primary biliary cirrhosis.

Authors:  W R Kim; R H Wiesner; T M Therneau; J J Poterucha; M K Porayko; R W Evans; G B Klintmalm; J S Crippin; R A Krom; E R Dickson
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  33 in total

1.  A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Authors:  Fernanda Q Onofrio; Gideon M Hirschfield; Aliya F Gulamhusein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

Review 2.  Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics.

Authors:  Amitkumar Patel; Anil Seetharam
Journal:  J Clin Exp Hepatol       Date:  2016-10-21

3.  Effects of corilagin on alleviating cholestasis via farnesoid X receptor-associated pathways in vitro and in vivo.

Authors:  Fan Yang; Yao Wang; Gang Li; Juan Xue; Zhi-Lin Chen; Feng Jin; Lei Luo; Xuan Zhou; Qian Ma; Xin Cai; Hua-Rong Li; Lei Zhao
Journal:  Br J Pharmacol       Date:  2018-01-25       Impact factor: 8.739

4.  Distinctive HLA-II association with primary biliary cholangitis on the Island of Sardinia.

Authors:  Maria Grazia Clemente; Fulvia Frau; Matilde Bernasconi; Maria Doloretta Macis; Lucia Cicotto; Giampaolo Pilleri; Stefano De Virgiliis; Paolo Castiglia; Patrizia Farci
Journal:  United European Gastroenterol J       Date:  2016-08-09       Impact factor: 4.623

5.  The latest research trends in primary biliary cholangitis: a bibliometric analysis.

Authors:  Yu Zhao; Zhenjie Yin; Huang Du; Kangming Huang; Fajing Zhang; Hongbin Chen
Journal:  Clin Exp Med       Date:  2022-04-07       Impact factor: 3.984

6.  Familiarity Breeds Strategy: In Silico Untangling of the Molecular Complexity on Course of Autoimmune Liver Disease-to-Hepatocellular Carcinoma Transition Predicts Novel Transcriptional Signatures.

Authors:  Soumyadeep Mukherjee; Arpita Kar; Najma Khatun; Puja Datta; Avik Biswas; Subhasis Barik
Journal:  Cells       Date:  2021-07-29       Impact factor: 6.600

Review 7.  Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications.

Authors:  Katriina Nemes; Fredrik Åberg; Helena Gylling; Helena Isoniemi
Journal:  World J Hepatol       Date:  2016-08-08

Review 8.  Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis.

Authors:  Despoina Dimopoulou; Theodoros Dimitroulas; Evangelos Akriviadis; Alexandros Garyfallos
Journal:  Rheumatol Int       Date:  2015-09-28       Impact factor: 2.631

9.  Axillobifemoral Bypass for Aortitis Syndrome in a Living-Donor Liver Transplant Patient.

Authors:  Naoto Fukunaga; Kenji Uryuhara; Tadaaki Koyama
Journal:  Ann Vasc Dis       Date:  2016-04-14

Review 10.  Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents.

Authors:  Sho Hasegawa; Masato Yoneda; Yusuke Kurita; Asako Nogami; Yasushi Honda; Kunihiro Hosono; Atsushi Nakajima
Journal:  Drugs       Date:  2021-06-17       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.